Parallel in vivo and in vitro melanoma RNAi dropout screens reveal synthetic lethality between hypoxia and DNA damage response inhibition.

To identify factors preferentially necessary for driving tumor expansion, we performed parallel in vitro and in vivo negative-selection short hairpin RNA (shRNA) screens. Melanoma cells harboring shRNAs targeting several DNA damage response (DDR) kinases had a greater selective disadvantage in vivo than in vitro, indicating an essential contribution of these factors during tumor expansion. In growing tumors, DDR kinases were activated following hypoxia. Correspondingly, depletion or pharmacologic inhibition of DDR kinases was toxic to melanoma cells, including those that were resistant to BRAF inhibitor, and this could be enhanced by angiogenesis blockade. These results reveal that hypoxia sensitizes melanomas to targeted inhibition of the DDR and illustrate the utility of in vivo shRNA dropout screens for the identification of pharmacologically tractable targets.

[1]  Joost B. Beltman,et al.  Heterogeneous Differentiation Patterns of Individual CD8+ T Cells , 2013, Science.

[2]  J. Bartek,et al.  Adaptation to the ionizing radiation-induced G2 checkpoint occurs in human cells and depends on checkpoint kinase 1 and Polo-like kinase 1 kinases. , 2006, Cancer research.

[3]  D. Tuveson,et al.  Suppression of BRAF(V599E) in human melanoma abrogates transformation. , 2003, Cancer research.

[4]  A. Pinder,et al.  A potent Chk1 inhibitor is selectively cytotoxic in melanomas with high levels of replicative stress , 2013, Oncogene.

[5]  J. Utikal,et al.  Improved survival with MEK inhibition in BRAF-mutated melanoma. , 2012, The New England journal of medicine.

[6]  Mohamed H. Sayegh,et al.  Identification of cells initiating human melanomas , 2008, Nature.

[7]  Sreenath V. Sharma,et al.  Exploiting the balance between life and death: targeted cancer therapy and "oncogenic shock". , 2010, Biochemical pharmacology.

[8]  E. Fuchs,et al.  RNAi screens in mice identify physiological regulators of oncogenic growth , 2013, Nature.

[9]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[10]  Kam Y. J. Zhang,et al.  Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity , 2008, Proceedings of the National Academy of Sciences.

[11]  Alan Ashworth,et al.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy , 2005, Nature.

[12]  A. Giaccia,et al.  Oxygen sensing and the DNA-damage response. , 2007, Current opinion in cell biology.

[13]  Corbin E. Meacham,et al.  In Vivo RNAi Screening Identifies Regulators of Actin Dynamics as Key Determinants of Lymphoma Progression , 2009, Nature Genetics.

[14]  A. Giaccia,et al.  Hypoxic Conditions Atm Activation and Signaling Under , 2008 .

[15]  Nicola J. Curtin,et al.  DNA repair dysregulation from cancer driver to therapeutic target , 2012, Nature Reviews Cancer.

[16]  S. Morrison,et al.  Heterogeneity in Cancer: Cancer Stem Cells versus Clonal Evolution , 2009, Cell.

[17]  Irving L. Weissman,et al.  Human Melanoma Initiating Cells Express Neural Crest Nerve Growth Factor Receptor CD271 , 2010, Nature.

[18]  Shuxia Zhao,et al.  Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors. , 2013, Cancer discovery.

[19]  Brian Keith,et al.  HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression , 2011, Nature Reviews Cancer.

[20]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[21]  M. Ellis,et al.  Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. , 2012, The Journal of clinical investigation.

[22]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[23]  Mark T. W. Ebbert,et al.  A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer , 2012, Breast Cancer Research and Treatment.

[24]  Ramon Arens,et al.  Dissecting T cell lineage relationships by cellular barcoding , 2008, The Journal of experimental medicine.

[25]  W. Kaelin.  The Concept of Synthetic Lethality in the Context of Anticancer Therapy , 2005, Nature Reviews Cancer.

[26]  E. Sausville,et al.  Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors , 2014, Cancer Chemotherapy and Pharmacology.

[27]  G. McArthur,et al.  Efficacy of CHK inhibitors as single agents in MYC-driven lymphoma cells , 2012, Oncogene.

[28]  Michael B Atkins,et al.  Which drug, and when, for patients with BRAF-mutant melanoma? , 2013, The Lancet. Oncology.

[29]  T. Shlomi,et al.  A key role for mitochondrial gatekeeper pyruvate dehydrogenase in oncogene-induced senescence , 2013, Nature.

[30]  Jonathan Maybaum,et al.  Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. , 2010, Cancer research.

[31]  H. Piwnica-Worms,et al.  Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics. , 2011, Trends in molecular medicine.

[32]  Hong Wu,et al.  mTOR is activated in the majority of malignant melanomas. , 2008, The Journal of investigative dermatology.

[33]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[34]  S. Morrison,et al.  Efficient tumor formation by single human melanoma cells , 2008, Nature.

[35]  Takashi Asai,et al.  The Checkpoint Kinase Inhibitor AZD7762 Potentiates Chemotherapy-Induced Apoptosis of p53-Mutated Multiple Myeloma Cells , 2012, Molecular Cancer Therapeutics.

[36]  W. Kaelin,et al.  Gleevec: Prototype or Outlier? , 2004, Science's STKE.

[37]  Ji Luo,et al.  Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.

[38]  A. Harris,et al.  Hypoxia-inducible factors 1alpha and 2alpha are related to vascular endothelial growth factor expression and a poorer prognosis in nodular malignant melanomas of the skin. , 2003, Melanoma research.

[39]  Alexander Roesch,et al.  A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth , 2010, Cell.

[40]  C. Sawyers.  Making progress through molecular attacks on cancer. , 2005, Cold Spring Harbor symposia on quantitative biology.

[41]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[42]  E. Hammond,et al.  Targeting Hypoxic Cells through the DNA Damage Response , 2010, Clinical Cancer Research.

[43]  M. Herlyn,et al.  Microenvironmental influences in melanoma progression , 2007, Journal of cellular biochemistry.

[44]  S. Morrison,et al.  Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. , 2010, Cancer cell.

[45]  Dirk Schadendorf,et al.  Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group , 2012 .